197 related articles for article (PubMed ID: 36280455)
1. Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.
Rubinstein M; Shen S; Monk BJ; Tan DSP; Nogueira-Rodrigues A; Aoki D; Sehouli J; Makker V
Gynecol Oncol; 2022 Dec; 167(3):540-546. PubMed ID: 36280455
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
3. Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.
Heffernan K; Nikitas FS; Shukla U; Camejo HS; Knott C
Gynecol Oncol; 2022 Aug; 166(2):317-325. PubMed ID: 35752507
[TBL] [Abstract][Full Text] [Related]
4. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
Ackroyd SA; Huang ES; Kurnit KC; Lee NK
Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
[TBL] [Abstract][Full Text] [Related]
6. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
Michener CM; Peterson G; Kulp B; Webster KD; Markman M
J Cancer Res Clin Oncol; 2005 Sep; 131(9):581-4. PubMed ID: 15959825
[TBL] [Abstract][Full Text] [Related]
8. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
Nagao S; Nishio S; Michimae H; Tanabe H; Okada S; Otsuki T; Tanioka M; Fujiwara K; Suzuki M; Kigawa J
Gynecol Oncol; 2013 Dec; 131(3):567-73. PubMed ID: 24076450
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
Dioun S; Chen L; De Meritens AB; St Clair CM; Hou JY; Khoury-Collado F; Pua T; Hershman DL; Wright JD
Gynecol Oncol; 2024 Mar; 182():70-74. PubMed ID: 38262241
[TBL] [Abstract][Full Text] [Related]
10. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
Sorbe B; Andersson H; Boman K; Rosenberg P; Kalling M
Int J Gynecol Cancer; 2008; 18(4):803-8. PubMed ID: 17944917
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
Aghajanian C; Filiaci V; Dizon DS; Carlson JW; Powell MA; Secord AA; Tewari KS; Bender DP; O'Malley DM; Stuckey A; Gao J; Dao F; Soslow RA; Lankes HA; Moore K; Levine DA
Gynecol Oncol; 2018 Aug; 150(2):274-281. PubMed ID: 29804638
[TBL] [Abstract][Full Text] [Related]
13. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR; Chase DM; Slomovitz BM; dePont Christensen R; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; Coleman RL; Powell MA;
N Engl J Med; 2023 Jun; 388(23):2145-2158. PubMed ID: 36972026
[TBL] [Abstract][Full Text] [Related]
14. A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
Ang JE; Shah RN; Everard M; Keyzor C; Coombes I; Jenkins A; Thomas K; A'Hern R; Jones RL; Blake P; Gabra H; Hall G; Gore ME; Kaye SB
Ann Oncol; 2009 Nov; 20(11):1787-93. PubMed ID: 19542250
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
Nomura H; Aoki D; Takahashi F; Katsumata N; Watanabe Y; Konishi I; Jobo T; Hatae M; Hiura M; Yaegashi N
Ann Oncol; 2011 Mar; 22(3):636-642. PubMed ID: 20696677
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Lorusso D; Ferrandina G; Colombo N; Pignata S; Pietragalla A; Sonetto C; Pisano C; Lapresa MT; Savarese A; Tagliaferri P; Lombardi D; Cinieri S; Breda E; Sabatucci I; Sabbatini R; Conte C; Cecere SC; Maltese G; Scambia G
Gynecol Oncol; 2019 Dec; 155(3):406-412. PubMed ID: 31677820
[TBL] [Abstract][Full Text] [Related]
17. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
18. A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial.
Hori K; Nishio S; Ushijima K; Kasamatsu Y; Kondo E; Takehara K; Ito K
J Gynecol Oncol; 2021 Jul; 32(4):e64. PubMed ID: 34085798
[TBL] [Abstract][Full Text] [Related]
19. Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma.
Arimoto T; Nakagawa S; Yasugi T; Yoshikawa H; Kawana K; Yano T; Taketani Y
Gynecol Oncol; 2007 Jan; 104(1):32-5. PubMed ID: 16996113
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma.
Walker CA; Spirtos AN; Miller DS
Expert Rev Anticancer Ther; 2023 Apr; 23(4):361-368. PubMed ID: 36944439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
